Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... Aug. 7 SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced ... 30, 2008. For the three months ended June 30, 2008, ... of $7.2 million. For,the six months ended June 30, 2008, ... The revenue in the six month period includes $10.8,million of ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... (the "Arrangement Agreement") dated,August 6, 2008 with, among ... Chromos, and Modatech Systems Inc. ("Modatech"),pursuant to which ... effect a plan,of arrangement (the "Arrangement") under section ...
Cached Biology Technology:SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched an innovative ... that enhances care coordination among social service and care providers ... second $1 million grant from the Alliance Healthcare Foundation to ... be recognized as a "Live Well San Diego" partner on ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 6 December 2007 Elsevier is pleased to announce ... Leukotrienes & Essential Fatty Acids (PLEFA) will become the ... of Fatty Acids and Lipids (ISSFAL). 2008 ... in 1978 as Prostaglandins and Medicine by the late ...
... could solve the growing energy demands of millions of ... the region,s tensions pertaining to oil supplies through hydroelectric ... untold ecological harm and displace countless people from their ... Global Environmental Issues, Roelof Dirk Schuiling of Utrecht University ...
... in a Fully Flexible ... ISO-Compliant ... Microsystems, Inc., a,pioneering developer of fingerprint imaging and authentication ... Card. This biometrically-authenticated credential,features a fully-embedded biometric system. Fidelica,s ...
Cached Biology News:Dam the Red Sea and release gigawatts 2Fidelica Microsystems Announces Biometrically-Authenticated Smart Card 2
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
... Development kit contains the basic components required ... measure natural and recombinant mouse Dickkopf homolog-1 ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
Biology Products: